Search Results - "Paz‐Priel, Ido" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

by Mahlangu, Johnny, Oldenburg, Johannes, Paz-Priel, Ido, Negrier, Claude, Niggli, Markus, Mancuso, M. Elisa, Schmitt, Christophe, Jiménez-Yuste, Victor, Kempton, Christine, Dhalluin, Christophe, Callaghan, Michael U, Bujan, Willem, Shima, Midori, Adamkewicz, Joanne I, Asikanius, Elina, Levy, Gallia G, Kruse-Jarres, Rebecca
Published in The New England journal of medicine (30.08.2018)

Get full text

Journal Article

Low immunogenicity of emicizumab in persons with haemophilia A

Low immunogenicity of emicizumab in persons with haemophilia A

by Schmitt, Christophe, Emrich, Thomas, Chebon, Sammy, Fernandez, Elena, Petry, Claire, Yoneyama, Koichiro, Kiialainen, Anna, Howard, Monet, Niggli, Markus, Paz‐Priel, Ido, Chang, Tiffany
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2021)

Get full text

Journal Article

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

by Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2022)

Get full text

Journal Article

Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)

Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)

by Mackensen, Sylvia, Catalani, Olivier, Asikanius, Elina, Paz‐Priel, Ido, Lehle, Michaela, Trask, Peter
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2020)

Get full text

Journal Article

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

by Nishimura, Jun‐ichi, Usuki, Kensuke, Ramos, Julia, Ichikawa, Satoshi, Buri, Muriel, Kiialainen, Anna, Sostelly, Alexandre, Peffault de Latour, Régis, Paz‐Priel, Ido, Röth, Alexander
Published in British journal of haematology (01.08.2022)

Get full text

Journal Article

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

by Skinner, Mark W., Négrier, Claude, Paz‐Priel, Ido, Chebon, Sammy, Jiménez‐Yuste, Victor, Callaghan, Michael U., Lehle, Michaela, Niggli, Markus, Mahlangu, Johnny, Shapiro, Amy, Shima, Midori, Campinha‐Bacote, Avrita, Levy, Gallia G., Oldenburg, Johannes, Mackensen, Sylvia, Pipe, Steven W.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.09.2021)

Get full text

Journal Article

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays

by Adamkewicz, Joanne I., Kiialainen, Anna, Paz‐Priel, Ido
Published in International journal of laboratory hematology (01.04.2020)

Get full text

Journal Article

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

by Parnes, Aric, Mahlangu, Johnny N., Pipe, Steven W., Paz‐Priel, Ido, Lehle, Michaela, Trask, Peter C., Jiménez‐Yuste, Víctor
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.11.2021)

Get full text

Journal Article

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

by Kempton, Christine, Trask, Peter, Parnes, Aric, Niggli, Markus, Campinha‐Bacote, Avrita, Callaghan, Michael, O'Connell, Niamh, Paz‐Priel, Ido, Mahlangu, Johnny N.
Published in Haemophilia : the official journal of the World Federation of Hemophilia (01.03.2021)

Get full text

Journal Article

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

by Valls, Raquel, Wagg, Jonathan, Paz-Priel, Ido, Man, Gabriel, Artigas, Laura, Jaccard, Georges, Coma, Mireia, Schmitt, Christophe
Published in Scientific reports (21.06.2023)

Get full text

Journal Article

Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors

Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors

by Nishimura, Jun‐ichi, Soubret, Antoine, Arase, Noriko, Buatois, Simon, Hotta, Masaki, Charoin, Jean‐Eric, Ito, Yoshikazu, Sreckovic, Sasha, Takamori, Hiroyuki, Bucher, Christoph, Ueda, Yasutaka, Hernández‐Sánchez, Jules, Gotanda, Keisuke, Jordan, Gregor, Shinomiya, Kenji, Ramos, Julia, Kim, Jin Seok, Panse, Jens, Latour, Régis Peffault, Röth, Alexander, Morii, Eiichi, Schrezenmeier, Hubert, Isaka, Yoshitaka, Sica, Simona, Kanakura, Yuzuru, Yoon, Sung‐Soo, Kinoshita, Taroh, Paz‐Priel, Ido, Sostelly, Alexandre
Published in Clinical pharmacology and therapeutics (01.04.2023)

Get full text

Journal Article

Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic Stem Cells

Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic Stem Cells

by Zhang, Jing, Li, Li, Baldwin, Jr, Albert S, Friedman, Alan D, Paz-Priel, Ido
Published in PloS one (23.06.2015)

Get full text

Journal Article

Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome

Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome

by Paz-Priel, Ido, MD, Cooke, David W., MD, Chen, Allen R., MD, PhD
Published in The Journal of pediatrics (01.02.2011)

Get full text

Journal Article

Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma

Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma

by PAZ-PRIEL, Ido, LONG, Lauren, HELMAN, Lee J, MACKALL, Crystal L, WAYNE, Alan S
Published in Journal of clinical oncology (20.04.2007)

Get full text

Journal Article

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology

by Trucco, Matteo M, Awad, Ola, Wilky, Breelyn A, Goldstein, Seth D, Huang, Ruili, Walker, Robert L, Shah, Preeti, Katuri, Varalakshmi, Gul, Naheed, Zhu, Yuelin J, McCarthy, Edward F, Paz-Priel, Ido, Meltzer, Paul S, Austin, Christopher P, Xia, Menghang, Loeb, David M
Published in PloS one (06.11.2013)

Get full text

Journal Article

Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma

Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma

by Huynh-Le, Minh-Phuong, Walker, Amanda J., Kominers, Scott Duke, Paz-Priel, Ido, Wharam, Moody D., Terezakis, Stephanie A.
Published in Pediatric blood & cancer (01.07.2014)

Get full text

Journal Article

CCAAT/Enhancer Binding Protein α (C/EBPα) and C/EBPα Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-κB p50

CCAAT/Enhancer Binding Protein α (C/EBPα) and C/EBPα Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-κB p50

by Paz-Priel, Ido, Cai, Dong Hong, Wang, Dehua, Kowalski, Jeanne, Blackford, Amanda, Liu, Huaitian, Heckman, Caroline A., Gombart, Adrian F., Koeffler, H. Phillip, Boxer, Linda M., Friedman, Alan D.
Published in Molecular cancer research (01.10.2005)

Get full text

Journal Article

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

by Adamkewicz, Joanne I., Chen, David C., Paz-Priel, Ido
Published in Thrombosis and haemostasis (01.07.2019)

Get full text

Journal Article

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

by Callaghan, Michael U., Negrier, Claude, Paz-Priel, Ido, Chang, Tiffany, Chebon, Sammy, Lehle, Michaela, Mahlangu, Johnny, Young, Guy, Kruse-Jarres, Rebecca, Mancuso, Maria Elisa, Niggli, Markus, Howard, Monet, Bienz, Nives Selak, Shima, Midori, Jiménez-Yuste, Victor, Schmitt, Christophe, Asikanius, Elina, Levy, Gallia G., Pipe, Steven W., Oldenburg, Johannes
Published in Blood (22.04.2021)

Get full text

Journal Article

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

by Nishimura, Jun-ichi, Usuki, Kensuke, Ramos, Julia, Ichikawa, Satoshi, Hernández-Sánchez, Jules, Kiialainen, Anna, Sostelly, Alexandre, Peffault De Latour, Regis, Paz-Priel, Ido, Röth, Alexander
Published in Blood (05.11.2020)

Get full text

Journal Article